Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | NADK | O95544 | 1/20 | 0.39 |
| ▸ | AMD1 | P17707 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213150 | 1.00 | AHCY (0.58) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9217727 | 0.87 | AHCY (0.60) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9217733 | 0.87 | AHCY (0.60) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9214589 | 0.77 | AHCY (0.72) | AHCY | |
| SCHEMBL9217782 | 0.77 | AHCY (0.72) | AHCY | |
| SCHEMBL9214583 | 0.77 | AHCY (0.72) | AHCY | |
| SCHEMBL9215301 | 0.75 | AHCY (0.66) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9215307 | 0.75 | AHCY (0.66) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9223106 | 0.73 | AHCY (0.64) | AHCYPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9223113 | 0.73 | AHCY (0.64) | AHCYPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347852-B1 | Novel neplanocin derivatives | MERRELL DOW PHARMA (US) | 1995-08-23 | — | — | EP | claimed |
| EP-0347852-A2 | Novel neplanocin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-27 | — | — | EP | claimed |
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-8211869-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-07-03 | — | — | US | disclosed |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-03-29 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
| EP-0347852-B1 | Novel neplanocin derivatives | MERRELL DOW PHARMA (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0347852-A2 | Novel neplanocin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | AHCY 2998/4885PDE4A 4745/4885PDE4B 4588/4885 |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | HCCS, MCL1, AHR | AHCY 1749/4885PDE4A 4807/4885PDE4B 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.